Prelude Therapeutics Inc.
Prelude Therapeutics Inc. is listed today as Prelude Therapeutics Incorporated: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2020 | $50 M | No. 4 | $50 to $250 million | equity | SEC | |
| May 2019 | $30 M | No. 3 | $10 to $50 million | equity | SEC | |
| Oct 2017 | $30 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jun 2016 | $5 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Prelude Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2020).
SEC Form D · Aug 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2020
That is all the official record says: Prelude Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Prelude Therapeutics Inc. are on record.
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 667, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Baker Bros. Advisors (GP) LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Baker Bros. Advisors LP | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Baker Brothers Life Sciences LP | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| OrbiMed Capital GP VI LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Paul A. Friedman | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 8 investors.
Largest shareholders today
Institutions holding Prelude Therapeutics Incorporated shares, as of Sep 30, 2026.
- Orbimed Advisors LLC$54 M17.20%
- Baker Bros. Advisors LP$40 M12.69%
- Ra Capital Management, L.P.$25 M8.11%
- Soleus Capital Management, L.P.$13 M4.23%
- Affinity Asset Advisors, LLC$10 M3.26%
- Kynam Capital Management, LP$9 M2.90%
- Vanguard Capital Management LLC$7 M2.38%
- BlackRock, Inc.$7 M2.33%
- Two Sigma Investments, LP$4 M1.23%
- Sphera Funds Management LTD.$3 M1.06%
- Acadian Asset Management LLC$3 M1.06%
- Geode Capital Management, LLC$3 M0.90%
- Goldman Sachs Group Inc$3 M0.84%
- State Street Corp$3 M0.83%
- UBS Group AG$2 M0.70%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew C. Combs | Executive officer | Aug 2020 |
| Brian C. Piper | Executive officer | Aug 2020 |
| Christopher C. Pierce | Executive officer | Aug 2020 |
| David C. Mauro | Executive officer | Aug 2020 |
| Deborah C. Morosini | Executive officer | Aug 2020 |
| Krishna Vaddi | Executive officer | Aug 2020 |
| Peggy C. Scherle | Executive officer | Aug 2020 |
| David Mauro | Executive officer | Jun 2019 |
| Peggy Scherle | Executive officer | Jun 2019 |
| Juan Luengo | Vice President of Issuer | Aug 2018 |
| David Bonita | Director | Aug 2020 |
| Kelvin Neu | Director | Aug 2020 |
| Krishna Vaddi | Director | Aug 2020 |
| Mardi C. Dier | Director | Aug 2020 |
| Paul Friedman | Director | Aug 2020 |
| Victor Sandor | Director | Aug 2020 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.